Covid-19 roundup: J&J to apply for booster authorization this week as adcomms are set; BioNTech CEO Ugur Sahin predicts need for new vaccine formulation
Two weeks after releasing new data showing its Covid-19 booster shot bumped protection against moderate to severe disease up to 75% worldwide, J&J is reportedly preparing an application for the FDA.
The pharma is planning on asking US regulators early this week to authorize its Covid-19 booster shot, unnamed sources told the New York Times.
The FDA authorized Pfizer and BioNTech’s booster shot last month, and is reportedly considering a half-dose booster of Moderna’s vaccine. The agency put out word Friday that its Vaccines and Related Biological Products Advisory Committee will meet on Oct. 14 and 15 to discuss Moderna and J&J’s boosters, respectively.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters